Acne vulgaris is the eighth most common disease worldwide and presents with inflammatory and noninflammatory skin lesions along with other dermal abnormalities. Oral spironolactone is used for treating acne vulgaris due to its antiandrogenic properties and inhibition of sebogenesis. Recent evidence shows that spironolactone in topical form has similar efficacy to its oral form with comparatively fewer adverse events associated with its use. However, to establish an evidence-based understanding, this systematic review aims to investigate the efficacy and safety of topical spironolactone in the treatment of acne vulgaris. PubMed, Clini calTr ials.gov, Cochrane library, and Google Scholar were comprehensively searched from the date of inception till March 18, 2022 All the clinical trials experimenting with the role of topical spironolactone in the treatment of acne were included. Articles examining the effects of oral spironolactone or other topical agents were excluded. The Cochrane risk of bias assessment tool (RoB 2.0, version 2019) was used to assess the risk of bias in each study. The study findings have been reported in line with PRISMA 2020 guidelines. The literature search yielded 600 articles. Five clinical trials with 195 patients were included in this review. Out of the five trials, two showed a high risk of bias while three had overall some concerns. Patients treated with topical spironolactone showed a significant decrease in the number of papules (p = 0.004), closed comedones (p < 0.05), and lesions (p < 0.05). Compared to placebo, treatment with 5% spironolactone showed a significant decrease in total lesion count (p = 0.007). In addition, 2% spironolactone showed efficacy over clindamycin and reduced the number of comedones (p < 0.0001), papules (p < 0.0001), and pustules (p < 0.0001) while the acne severity index was also considerably lowered (p < 0.0001). Spironolactone was not found to affect significant skin hydration, sebum, elasticity, melanin, and redness (p > 0.05). Topical spironolactone yields better results than other first-line treatments for acne and displays fewer side effects. However, further large-scale clinical trials are required before spironolactone can be used as the preferred treatment in the clinical management of acne.
Monkeypox is a rare zoonotic disease caused by the monkeypox virus, which spreads by direct contact mainly, thus having the propensity to cause future epidemics. The current review aimed to provide an up-todate literature analysis for evaluating scientific data on monkeypox. A bibliometric analysis was conducted through eight electronic databases. The search period was from May 2022 to December 2023. All the articles were exported to Mendeley (Elsevier, Amsterdam, Netherlands). The literature search resulted in 415 relevant research articles. The growth of publications gradually rose, initiated in January 2022, leading to a rapid upsurge in May 2022. A total of 409 documents reported the number of citations, with two articles documenting the highest number, ranging from 146-150 and 216-220. The European region (EURO) dominated in publishing research articles on monkeypox, with the United States having the highest number of reports (n = 41; 9.87%), followed by the United Kingdom (n = 35; 8.43%) and Italy (n = 15; 3.61%). There were 82 funding agencies that funded 44 research articles, whereas 371 were not funded by any funding agency. Our analysis has presented the outline of the research articles published on monkeypox virusrelated literature during the current outbreak. Research articles should be financially and administratively supported. Future research is required to expand research on the monkeypox virus, as there is a growing demand for original articles.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.